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Abstract: The treatment of Parkinson's disease (PD) with levodopa is very effective. However, 
over time, motor complications (MCs) such as ON-OFF fluctuations appear, restricting the 
patient from leading a normal life. Gathering accurate information about the clinical status of 
the patient is essential for planning treatment and assessing its effect. Systems such as the 
REMPARK system, capable of accurately and reliably monitoring ON-OFF fluctuations, are of 
great interest. Objective: To validate the ON-OFF detection function through the REMPARK 
System. Methods: Forty-one patients with moderate to severe idiopathic PD were recruited. 
Patients with motor fluctuations, freezing of gait and/or dyskinesia and who were able to walk 
unassisted in the OFF phase, were included in the study. Patients wore the REMPARK System 
for 3 days and completed a diary of their motor state once every hour. Results: The record 
obtained by the REMPARK System, compared with patient-completed diaries, demonstrated 
97% sensitivity in detecting OFF states and 88% specificity. Conclusion: The REMPARK System 
detects an accurate evaluation of ON-OFF fluctuations in PD; this technology paves the way for 
an optimisation of the symptomatic control of PD motor symptoms as well as an accurate 
assessment of medication efficacy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION  
Parkinson's disease (PD) is complicated over time by both motor complications (MCs)[1] and 
non-motor complications (NMCs)[2]. Symptomatic control of MCs can be challenging and 
requires frequent adjustment of therapy on account of unpredictable therapeutic responses. 
Gathering accurate information about a patient's condition throughout the day is essential to 
plot the optimal treatment plan. In clinical practice, the only method currently available is 
based on diaries filled in by patients and their caregivers, recording hours of ON-OFF and the 
presence of dyskinesias[3]. However, this method has limitations that make it unreliable, such 
as motor and cognitive difficulties impeding the ability to complete the diary, and the 
subjective nature of the self-evaluation[4]. Hence, there is considerable research interest in 
potential solutions that can improve disease management[5-8]. Wearable inertial sensors, 
have been widely used to analyse symptoms of PD such as tremor, bradykinesia, or dyskinesia. 
Some studies have examined the monitoring of motor states, but the results demonstrated 
only modest sensitivity and specificity[9-11]. Other studies used more than one sensor[12-16], 
resulting in less comfort for the patient. Moreover, monitoring was performed in controlled 
clinical environments, where conditions are different to patients’ daily life[17]. The REMPARK 
system (REMPARK Personal health device for the remote and autonomous management of 
Parkinson’s disease, FP7 project REMPARK ICT-287677) is a wearable system, developed 
between 2011-2015, to monitor motor states through a system requiring a single sensor. 
Analogous to the “Holter” for the monitoring of cardiac parameters, the REMPARK System is 
designed to record the patient's condition during daylight hours and to aid in managing the 
disease via the smartphone. The object of this study is to validate the REMPARK System as a 
system for automatic registration of ON-OFF fluctuations associated with PD treatment. 
METHODS 
Subjects 
A prospective pilot study was conducted, in which the recruitment was carried out following a 
convenience sampling among patients from the different centres participating in the REMPARK 
project: UParkinson-Teknon, (Barcelona), Fondazione Santa Lucia (Rome), Maccabi Healthcare-
Services (Tel Aviv) and the National University of Ireland Galway (Galway). The investigation 
was conducted in accordance with the Helsinki declaration 1964 (2008 Revision) and Good 
Clinical Practice guidelines. Institutional Review Board (IRB) approval was obtained from each 
clinical centre. All participants gave written informed consent and the following inclusion 
criteria were applied: a clinical diagnosis of idiopathic PD[18]; motor fluctuations, freezing of 
gait and/or dyskinesia; able to walk unassisted in the OFF phase; between 50 and 80 years of 
age and the ability to understand the potential risks and benefits of the study. 
Subjects were excluded if they had other health problems that hampered physical activity and 
gait, were unable to recognise the ON-OFF fluctuations after proper training, met the criteria 
for dementia, according to DSM-IV-TR[19], were unwilling to cooperate, or were participating 
in other clinical trials. 
Equipment, variables and instruments 
Assessment Instruments 
Patients’ full clinical histories were collected. Standardised neurological assessment included 
the Unified Parkinson’s Disease Rating Scale (UPDRS)[20] and Hoehn & Yahr (H&Y) staging[21]. 
Patients also completed a questionnaire to detect motor fluctuations and dyskinesia, and the 
Mini-Mental State (MMSE)[22] to evaluate  cognitive function. Usability was assessed by using 
the Usability Scale (SUS)[23], and the QUEST-questionnaire[24]  to evaluate satisfaction. 
Equipment 
The equipment used in the study consisted of the wearable elements of the REMPARK is 
described in a previous article [25]. 
Design and procedures 
This is a prospective transversal pilot study, in which each participant wears the REMPARK 
System under real conditions during 3 consecutive days. The study took 2 extra days to make 
individual adjustments and adaptations (figure 1). 
The first stage (day 0) focused on the recruitment of the subjects. Socio-demographic data, 
neurological data and written informed consent, were collected from all subjects enrolled in 
the study. The second phase (day 1) consisted in training patients and caregivers on how to 
operate the REMPARK System and the method for recording motor status in the diary. In the 
third phase (days 2, 3 and 4), patients used the system in their daily life for a minimum of 8 
hours a day. In the diary, they recorded their motor status once every hour, timing of 
medication doses and their sleeping hours. A researcher went to the patient's home once a 
day and reviewed the proper functioning of the system. They administered the UPDRS part III 
to analyse the correlation between patient diary annotations and the actual motor status. In 
addition, approximately every two hours, the researchers called patients to verify that the 
system was working and asked about their motor state at that time. The motor state recorded 
by researchers in these follow-up calls was compared with that scored by patients in the diary. 
In case of discrepancy, the corresponding period was excluded from the analysis. At the end of 
the 4th day, patients answered the usability and satisfaction questionnaires [23,24] and 
reported on additional technical incidences. 
REMPARK System-On-Off Detection Algorithms  
The estimation of the motor state is based on a set of real-time algorithms applied to the 
sensor. A first algorithm analyses gait[26]  and a second one analyses dyskinesia[27]. A third 
algorithm merges the information of the first two, providing the motor state estimation (see 
Appendix) 
Validation against ON-OFF diaries  
The ON-OFF diaries completed by the patients were used as the gold standard. Given that 
diaries are known to lack reliability[4], we developed a number of strategies that would 
improve their validity: 
Firstly, the validity of diaries was evaluated based on clinicians’ expertise through variations in 
the UPDRS motor score. The validity of the gold standard has been evaluated based on an 
objective measure consisting in the correlation between UPDRS scores and motor states 
provided by patients at the time of diary recording. Motor state is represented with 2=OFF, 
1=Intermediate and 0=ON, so positive correlations are expected. Patients whose Pearson 
correlation coefficient was lower than 0.2 were not included in the study, since their ON-OFF 
diaries were considered not reliable to be used as gold standard. 
Secondly, motor states recorded by the researchers during calls were compared with the notes 
made by patients in their diaries. In case of discrepancy, the corresponding periods were 
excluded from the analysis. 
Thirdly, in order to consider a diary motor state record valid, it must appear two consecutive 
times in the diary, so that the patient demonstrates some consistency over a two-hour epoch. 
In the event of a motor state changing between two consecutive records, both records were 
excluded from the analysis, since the time in which the motor state changed is considered non-
reliable.  
Data Analysis 
Motor state estimations of the REMPARK System were compared with the annotations made 
by the patients. The comparison is done in terms of specificity and sensitivity for both ON and 
OFF motor states. Intermediate states have not been evaluated to ensure the validity of the 
reported motor state and because many patients only reported ON and OFF states. 
Consequently, REMPARK System validation is done as a binary diagnostic test in which positive 
cases correspond to reported OFF annotations and negative cases to the ON ones. This way, 
the accuracy in detecting OFF states is reported as sensitivity and the accuracy in ON states is 
given as specificity.  
RESULTS 
Fifty-four patients were initially contacted, 44 of whom met inclusion criteria and agreed to 
participate. Three of these patients did not complete the study procedure. The first due to lack 
of adherence to the study protocol and the second due to a health condition which required 
hospitalisation, not related to study devices or procedures. Forty-one patients completed the 
study days and evaluations (Figure 2). Table 1 shows detailed data of the characteristics of the 
participants. Of the 41 patients who completed the study, the data for 5 of them could not be 
analysed because the diary data was incomplete or unavailable. In addition, data from 3 
patients was removed due to a low Pearson correlation coefficient between UPDRS scores and 
the motor state reported by the patient (correlations:  -0.62, 0.06 and 0.2, respectively). Data 
from 33 patients were analysed. 
The average specificity and sensitivity achieved by the system in recognising ON-OFF motor 
states is 88% and 97% respectively. The system generated an average of 26.3 hourly-based 
motor state detections per patient over the 3 days (9.6 ON, 3.5 OFF and 13.2 in intermediate 
state). Thus, on average, for each of the three days, almost 9 hours of monitoring were 
provided by the system per day.  However, only those hours in which the patient reporting an 
ON or an OFF motor state coincided with the REMPARK system estimation were used. This 
resulted in validating 5 hours per patient (Table 2).  
Health-safety of the REMPARK System: During the experimental period, 7 participants 
presented “adverse events” on health. One of them had a “serious adverse event” that 
required hospitalisation. The most frequent adverse events were limb pain (n=3) and 
depressive symptoms (n=3). Neck pain was also reported (n=1). All adverse events, were 
considered as unrelated to the investigational device.  
Usability and user satisfaction: The median score of SUS in this study was 70 (IQR 25). A SUS 
score of more than 50 is considered acceptable, and above 68-70 good [23].In the QUEST-
questionnaire[24], no patient was "not satisfied at all" with the system. Five per cent were 
“not very satisfied", 20% "more or less satisfied" and 76% "satisfied" or "very satisfied". 
Comfort is the element with the lowest score and security with the highest. 
 
DISCUSSION 
Systems that monitor PD symptoms reliably and accurately can be very useful in optimising 
treatment in patients. Our study evaluated the accuracy of the REMPARK system for 
monitoring ON-OFF states in Parkinson’s patients in real conditions.  
 Despite the widespread use of patient diaries both in clinical practice and research settings for 
monitoring motor function, their limitations and subjectivity are well documented[28]. In our 
study we attempted to improve the reliability of the data obtained from the diaries (gold 
standard). Although this strategy reduces the number of patients’ records used, it ensures that 
the records employed to validate the system are reliable. When applying this method, the 
accuracy in detecting the ON state (specificity), achieves 88% and in detecting OFF states 97% 
(sensitivity). However, our findings need to be replicated in other cases, given the great clinical 
variation of patients affected by PD. An important aspect of the study is that the results were 
obtained under real life conditions, albeit those studies are very challenging, and may entail 
false positive or negative readings.  
One of the limitations of the system is that in order to assess the motor state, the patient must 
be walking or exhibit dyskinesias. Another limitation is the restricted sample size. However, 
because the average number of monitored hours is approximately 9, we consider that the 
number of detections made is sufficient to register the motor state. 
One of the main advantages in the detection of the motor state by the REMPARK system is 
that patients need to wear only a single sensor, making it compatible with an active life. In 
accordance with the results obtained in other studies[29], participants in our study also 
considered it to be user-friendly and were satisfied with the system. Although this is a very 
encouraging result, again it must be considered with some caution since the questionnaires 
were not anonymous.  
The data obtained in this study show that the REMPARK system is able to detect fluctuations in 
patients’ ON-OFF state. Given the increasing interest in this research topic, if the data is 
confirmed by further studies, it could prove to be an alternative tool to patients’ diaries, it 
being more reliable as it is not subject to possible bias and could also empower patients. 
Furthermore, the system paves the way for its clinical use in the future in related areas: the 
automatic control of continuous infusion pumps or to Deep Brain Stimulation management, 
the automatic application of external cues to guide the gait or for comprehensive and reliable 
analysis of changes in motor states. Additionally, it could contribute positively to the quality of 
life of PD patients[30]. In this way, further studies on a larger sample would be of interest to 
show improvement in quality of life after treatment optimisation by the REMPARK System. 
CONCLUSIONS 
There is a need for a reliable tool to detect a patient's motor-state, in order to adjust therapy. 
This paper has presented the validation of the REMPARK system for detecting the ON-OFF 
states with a high degree of accuracy. The reliable detection of the motor state of PD patients 
throughout the day can dramatically change the value of clinical drug trials. Furthermore, it 
allows for individual adjustment of symptomatic treatment with a high degree of accuracy.  
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